Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.

Journal for immunotherapy of cancer - 1 Dec 2020

Bai Hua, Duan Jianchun, Li Chengcheng, Xie Wenzhuan, Fang Wenfeng, Xu Yu, Wang Guoqiang, Wan Rui, Sun Jing, Xu Jiachen, Wang Xin, Fei Kailun, Zhao Zhengyi, Cai Shangli, Zhang Li, Wang Jie, Wang Zhijie

Abstract excerpt

BACKGROUND: Ephrin type-A receptors (EPHA) are members of family of receptor tyrosine kinases and are related to tumor immunogenicity and immune microenvironment, however, the association between EPHA mutation (EPHAmut ) and efficacy of immune checkpoint inhibitors (ICIs) has not been investigated in non-small cell lung cancer (NSCLC). METHODS: Multiple cohorts were used to assess the immunotherapeutic predictive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Brain Metastases and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Immunotherapy and Biomarkers

Share to Immunotherapy

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 33303576
DOI: 10.1136/jitc-2020-001315
PMCID: PMC7733211

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.PMID 33303576Read ↗

The role of EPHA3 mutation in the prognosis of non-small cell lung cancer patients receiving immunotherapySemantic proximity Read ↗

EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.Semantic proximity Read ↗

EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.Semantic proximity Read ↗

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma.Semantic proximity Read ↗

Systematic Pan-Cancer Analysis Reveals the Prognostic Value and Immunological Role of EPHX2Semantic proximity Read ↗

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinomaSemantic proximity Read ↗

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.Semantic proximity Read ↗

Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma.Semantic proximity Read ↗

Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma.Semantic proximity Read ↗

Comprehensive analysis of EphA2 in pan-cancer: A prognostic biomarker associated with cancer immunity.Semantic proximity Read ↗

EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers.Semantic proximity Read ↗

m 6 A‐modified EHD1 controls PD‐L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.